Insilico Medicine & ASKA Partner to Advance AI-Driven Treatments for Gynecological Diseases
Insilico Medicine, a clinical-stage biotechnology company specializing in generative artificial intelligence (AI) for drug discovery and development, has announced a strategic research partnership with ASKA Pharmaceutical Co., Ltd. (“ASKA”), a pharmaceutical firm focused on internal medicine, obstetrics, and gynecology. The collaboration is designed to uncover new therapeutic targets with strong development potential for complex gynecological conditions such as endometriosis, uterine fibroids, and adenomyosis, using Insilico’s proprietary AI platform, PandaOmics.
Gynecological disorders remain difficult to diagnose and treat, with limited therapeutic options and a significant global health impact. Data from the World Health Organization indicates that endometriosis alone affects around 190 million women worldwide, while uterine fibroids and adenomyosis impact even larger populations, often occurring together and significantly affecting reproductive health.
This partnership brings together ASKA’s expertise in women’s health treatments and Insilico’s advanced AI-powered biological analysis tools to tackle critical unmet medical needs and accelerate innovation. Under the agreement, Insilico will apply PandaOmics to generate and analyze disease hypotheses, while ASKA will carry out validation of the AI-identified targets with strong clinical potential.
The initiative will be led by Insilico’s Target Discovery team, headed by Dr. Frank Pun at its Hong Kong site. The team recently introduced Target Identification Pro (TargetPro), an AI-driven framework that integrates multi-modal data into disease-specific models to speed up target discovery. By identifying context-specific predictive patterns, TargetPro enhances accuracy in selecting targets most likely to progress to clinical development. It not only confirms known clinical targets but also proposes new, high-potential candidates suitable for rapid preclinical validation.
Dr. Frank Pun expressed enthusiasm about leading the collaboration, noting that prior preclinical validation of AI-identified targets in endometriosis highlights AI’s ability to generate meaningful insights within complex disease biology. He added that the latest TargetPro models are expected to support ASKA in advancing next-generation therapies for women globally.
Dr. Shuzo Watanabe, Head of the Innovative Drug Discovery Research Division at ASKA, also welcomed the collaboration, emphasizing the company’s commitment to integrating AI across its research and development processes. He stated that the partnership with Insilico Medicine is expected to accelerate the identification of high-quality and promising drug targets.
ASKA has been a long-time user of Insilico’s AI solutions, and this expanded collaboration builds on that foundation. Together, the companies aim to apply proven AI technologies to better understand the biological complexity of endometriosis, uterine fibroids, and adenomyosis, ultimately paving the way for innovative treatments and reinforcing their shared commitment to advancing women’s healthcare.
Gynecological disorders remain difficult to diagnose and treat, with limited therapeutic options and a significant global health impact. Data from the World Health Organization indicates that endometriosis alone affects around 190 million women worldwide, while uterine fibroids and adenomyosis impact even larger populations, often occurring together and significantly affecting reproductive health.
This partnership brings together ASKA’s expertise in women’s health treatments and Insilico’s advanced AI-powered biological analysis tools to tackle critical unmet medical needs and accelerate innovation. Under the agreement, Insilico will apply PandaOmics to generate and analyze disease hypotheses, while ASKA will carry out validation of the AI-identified targets with strong clinical potential.
The initiative will be led by Insilico’s Target Discovery team, headed by Dr. Frank Pun at its Hong Kong site. The team recently introduced Target Identification Pro (TargetPro), an AI-driven framework that integrates multi-modal data into disease-specific models to speed up target discovery. By identifying context-specific predictive patterns, TargetPro enhances accuracy in selecting targets most likely to progress to clinical development. It not only confirms known clinical targets but also proposes new, high-potential candidates suitable for rapid preclinical validation.
Dr. Frank Pun expressed enthusiasm about leading the collaboration, noting that prior preclinical validation of AI-identified targets in endometriosis highlights AI’s ability to generate meaningful insights within complex disease biology. He added that the latest TargetPro models are expected to support ASKA in advancing next-generation therapies for women globally.
Dr. Shuzo Watanabe, Head of the Innovative Drug Discovery Research Division at ASKA, also welcomed the collaboration, emphasizing the company’s commitment to integrating AI across its research and development processes. He stated that the partnership with Insilico Medicine is expected to accelerate the identification of high-quality and promising drug targets.
ASKA has been a long-time user of Insilico’s AI solutions, and this expanded collaboration builds on that foundation. Together, the companies aim to apply proven AI technologies to better understand the biological complexity of endometriosis, uterine fibroids, and adenomyosis, ultimately paving the way for innovative treatments and reinforcing their shared commitment to advancing women’s healthcare.
Companies